33 related articles for article (PubMed ID: 38479046)
1. Long-term disability progression in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a retrospective analysis of 101 patients.
Uzawa A; Mori M; Masuda H; Uchida T; Muto M; Ohtani R; Aoyama S; Kuwabara S
J Neurol Neurosurg Psychiatry; 2024 Jun; 95(7):626-629. PubMed ID: 38176896
[TBL] [Abstract][Full Text] [Related]
2. Rituximab maintenance treatment outcomes in patients with relapsing neuromyelitis optica spectrum disorder: a monocentric retrospective analysis.
Xiao L; Huang Y; Sun H; Gao S; Huang D; Wu L
Acta Neurol Belg; 2024 Jun; ():. PubMed ID: 38858290
[TBL] [Abstract][Full Text] [Related]
3. Are monoclonals the only panacea for treatment of aquaporin-4 positive NMOSD? Experience from a low-&middle-income (LMIC) region.
Dhamija K; Manjappaiah MG; Kandavel T; Mahadevan A; Netravathi M
Clin Neurol Neurosurg; 2024 Apr; 239():108212. PubMed ID: 38460428
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of rituximab in the treatment of neuromyelitis Optica Spectrum disorder.
Hayes MTG; Adam RJ; McCombe PA; Walsh M; Blum S
Mult Scler J Exp Transl Clin; 2024; 10(2):20552173241257876. PubMed ID: 38807849
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 vaccine response in Neuromyelitis Optica Spectrum Disorder.
Baba C; Kaya E; Ozcelik S; Ozdogar AT; Samadzade U; Cevik S; Calıskan C; Dogan Y; Ozakbas S
Clin Neurol Neurosurg; 2024 Mar; 238():108152. PubMed ID: 38382130
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive therapy in elderly patients with neuromyelitis optica spectrum disorder: a retrospective multicentre study.
Kim KH; Chung YH; Min JH; Han HJ; Kim SW; Shin HY; Kwon YN; Kim SM; Lim YM; Kim H; Lee EJ; Jeong SH; Hyun JW; Kim SH; Kim HJ
J Neurol Neurosurg Psychiatry; 2024 May; ():. PubMed ID: 38777578
[TBL] [Abstract][Full Text] [Related]
7. Development of RISS in two patients with NMOSD undergoing rituximab treatment: a case report.
Ersöz AS; Yaşargün DÖ; Mısırlı CH
Acta Neurol Belg; 2024 Jun; 124(3):1041-1042. PubMed ID: 37904077
[No Abstract] [Full Text] [Related]
8. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
Carnero Contentti E; Correale J
J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
[TBL] [Abstract][Full Text] [Related]
9. Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder.
Kim SH; Hyun JW; Kim HJ
Neurochem Int; 2019 Nov; 130():104347. PubMed ID: 30513364
[TBL] [Abstract][Full Text] [Related]
10. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
Nasir M; Hone L; Tallantyre E; Kelly P; Leite MI; Robertson N; Bestwick J; Huda S; Palace J; Dobson R
Mult Scler Relat Disord; 2024 May; 85():105528. PubMed ID: 38479046
[TBL] [Abstract][Full Text] [Related]
11. A long-term follow-up of rituximab treatment in 20 Chinese patients with neuromyelitis optica spectrum disorders.
Lu Q; Luo J; Hao H; Liu R; Jin H; Jin Y; Gao F
Mult Scler Relat Disord; 2020 May; 40():101933. PubMed ID: 31955136
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.
Tahara M; Oeda T; Okada K; Kiriyama T; Ochi K; Maruyama H; Fukaura H; Nomura K; Shimizu Y; Mori M; Nakashima I; Misu T; Umemura A; Yamamoto K; Sawada H
Lancet Neurol; 2020 Apr; 19(4):298-306. PubMed ID: 32199095
[TBL] [Abstract][Full Text] [Related]
13. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.
Kunchok A; Malpas C; Nytrova P; Havrdova EK; Alroughani R; Terzi M; Yamout B; Hor JY; Karabudak R; Boz C; Ozakbas S; Olascoaga J; Simo M; Granella F; Patti F; McCombe P; Csepany T; Singhal B; Bergamaschi R; Fragoso Y; Al-Harbi T; Turkoglu R; Lechner-Scott J; Laureys G; Oreja-Guevara C; Pucci E; Sola P; Ferraro D; Altintas A; Soysal A; Vucic S; Grand'Maison F; Izquierdo G; Eichau S; Lugaresi A; Onofrj M; Trojano M; Marriott M; Butzkueven H; Kister I; Kalincik T
Mult Scler Relat Disord; 2020 Feb; 38():101868. PubMed ID: 31877445
[TBL] [Abstract][Full Text] [Related]
14. Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
Barreras P; Vasileiou ES; Filippatou AG; Fitzgerald KC; Levy M; Pardo CA; Newsome SD; Mowry EM; Calabresi PA; Sotirchos ES
Neurology; 2022 Nov; 99(22):e2504-e2516. PubMed ID: 36240094
[TBL] [Abstract][Full Text] [Related]
15. Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study.
Paolilo RB; Hacohen Y; Yazbeck E; Armangue T; Bruijstens A; Lechner C; Apostolos-Pereira SL; Martynenko Y; Breu M; de Medeiros Rimkus C; Wassmer E; Baumann M; Papetti L; Capobianco M; Kornek B; Rostásy K; da Paz JA; Ciccarelli O; Lim M; Saiz A; Neuteboom R; Marignier R; Hemingway C; Sato DK; Deiva K
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32732259
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
